ALZN

Alzamend Neuro Inc

1.37

Oct 06 • 3:54 PM ET -0.04 (-2.84%)

1.37

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: APRE BCDA BIVI GOVX KAPA KPRX LNAI CALC CVM NEUP

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	6.61M
Enterprise Value	-0.98M
Income	-9.10M
Sales	0.00M
Book/sh	1.20
Cash/sh	1.57
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Jun 15, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.14
P/C	0.87
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.01
Current Ratio	3.01
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-2.29
EPS next Y	-0.87
EPS next Q	-0.23
EPS this Y	60.08%
EPS next Y	17.14%
EPS next 5Y	-
EPS past 3/5Y	76.63% 51.15%
Sales past 3/5Y	- -
EPS Y/Y TTM	73.61%
Sales Y/Y TTM	-
EPS Q/Q	47.33%
Sales Q/Q	-
Earnings	Sep 15
EPS/Sales Surpr.	0.00% -

Insider Own	2.66%
Insider Trans	484.64%
Inst Own	28.81%
Inst Trans	18.07%
ROA	-122.36%
ROE	-163.23%
ROIC	-156.77%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-20.36%
SMA50	-14.37%
SMA200	-11.83%
Trades

Shs Outstand	4.83M
Shs Float	4.70M
Short Float	2.62%
Short Ratio	1.36
Short Interest	0.12M
52W High	2.68 -48.88%
52W Low	0.84 63.10%
Volatility	16.14% 7.81%
ATR (14)	0.13
RSI (14)	34.48
Beta	0.38
Rel Volume	0.35
Avg Volume	90.72K
Volume	32,054

Perf Week	-24.73%
Perf Month	-17.47%
Perf Quarter	19.13%
Perf Half Y	47.85%
Perf YTD	-24.73%
Perf Year	-46.48%
Perf 3Y	-99.55%
Perf 5Y	-99.96%
Perf 10Y	-
Recom	1.00
Target Price	26.00
Prev Close	1.41
Price	1.37
Change %	-2.84%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-21	Initiated	Ascendiant Capital Markets	Buy	$8

Aug-20-26 08:00AM	Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC (PR Newswire) +7.24%
Aug-18-26 08:00AM	Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain (PR Newswire)
Aug-04-26 08:00AM	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending (PR Newswire) +8.21%
Apr-07-26 08:00AM	Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital (PR Newswire)
Mar-26-26 08:00AM	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions (PR Newswire) -22.28%
08:00AM	Loading…
Mar-16-26 08:00AM	Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital (PR Newswire)
Jan-26-26 09:40AM	Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-08-26 09:40AM	Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-20-25 07:50AM	EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth? (Zacks) -14.72%
Nov-19-25 08:00AM	Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital (PR Newswire) -5.33%
07:30AM	EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants (Benzinga)
Jul-28-25 08:00AM	Alzamend Neuro to Present at the 2025 Military Health System Research Symposium (GlobeNewswire) -6.42%
Jul-23-25 08:00AM	Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs (GlobeNewswire) -5.94%
Jun-16-25 08:00AM	Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule (GlobeNewswire)
May-29-25 08:00AM	Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) +63.86%
08:00AM	Loading…
May-19-25 08:00AM	Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) +5.88%
May-13-25 08:00AM	Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) -18.83%
07:30AM	EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants (Benzinga)
May-08-25 08:00AM	Alzamend Neuro Announces Reverse Stock Split (GlobeNewswire) -9.40%
May-07-25 08:00AM	Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital (GlobeNewswire) -6.22%
07:31AM	EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program (Benzinga)
Apr-08-25 09:55AM	Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks) -5.24%
Mar-28-25 10:42AM	Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? (Insider Monkey)
Mar-25-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital (GlobeNewswire)
Mar-18-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital (GlobeNewswire) +5.03%
Mar-11-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital (GlobeNewswire)
Mar-04-25 08:10AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital (GlobeNewswire)
Feb-25-25 08:00AM	Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital (GlobeNewswire)
07:30AM	EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 (Benzinga)
Feb-19-25 08:00AM	Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital (Business Wire) -6.48%
07:30AM	Loading…
07:30AM	EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels (Benzinga)
Jan-23-25 09:40AM	Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-15-25 08:00AM	Alzamend Neuro to Present at the Sequire Investor Summit (Business Wire)
Dec-18-24 08:00AM	Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo (Business Wire)
Dec-13-24 08:15AM	Alzamend Neuro says net cash gained by financing activity $8.3M (TipRanks)
Dec-12-24 08:00AM	Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs (Business Wire)
Nov-19-24 08:00AM	Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimers Transgenic Mice (Business Wire)
07:30AM	EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential (Benzinga)
Oct-16-24 08:00AM	Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
07:30AM	EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's (Benzinga)
Oct-15-24 08:00AM	Alzamend Neuro Regains Compliance with Nasdaq Listing Standards (Business Wire)
Oct-10-24 08:00AM	Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Groups Virtual Healthcare Conference (Business Wire)
Aug-26-24 08:00AM	Alzamend Neuro Issues Letter to Stockholders (Business Wire) -7.47%
Aug-19-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder (Business Wire) +186.78%
Aug-12-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder (Business Wire)
Aug-06-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder (Business Wire) -9.84%
05:32AM	Alzamend Neuro partners with Mass General for Alzheimers treatment trial (Clinical Trials Arena)
Aug-05-24 09:09AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimers Disease (Business Wire) -22.09%
07:30AM	EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study (Benzinga)
Jul-31-24 08:00AM	Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement (Business Wire)
Jul-12-24 08:00AM	Alzamend Neuro Announces Reverse Stock Split (Business Wire)
May-22-24 08:00AM	Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel (Business Wire)
May-14-24 08:00AM	Alzamend Neuro Announces Initial Closing of Private Placement (Business Wire) +18.81%
May-09-24 09:30AM	EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares (Benzinga) +11.74%
08:00AM	Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million (Business Wire)
May-07-24 08:00AM	Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program (Business Wire) -20.02%
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Mar-26-24 05:52AM	ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024 (InvestorPlace)
Dec-18-23 12:03PM	ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024 (InvestorPlace)
12:03PM	ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024 (InvestorPlace)
Dec-11-23 09:30AM	EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year (Benzinga) -6.54%
08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients (Business Wire)
Nov-20-23 08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients (Business Wire) -17.75%
Nov-16-23 08:00AM	Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement (Business Wire)
Nov-13-23 08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire) -6.85%
Oct-30-23 08:00AM	Alzamend Neuro Announces Reverse Stock Split (Business Wire) -24.62%
Oct-23-23 09:31AM	EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire)
Oct-02-23 09:30AM	EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder (Benzinga) -8.48%
08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Sep-22-23 08:00AM	Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement (Business Wire)
Aug-30-23 09:30AM	EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Jun-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study (Benzinga)
08:00AM	Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 (Business Wire)
Jun-13-23 08:00AM	Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Groups Virtual Healthcare Conference (Business Wire)
May-24-23 08:00AM	3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024 (InvestorPlace) +10.30%
May-11-23 12:38PM	3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year (InvestorPlace)
Apr-04-23 06:30AM	Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Apr-03-23 09:35AM	KILL Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) +15.29%
09:34AM	EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine (Benzinga)
08:50AM	Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Mar-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial (Benzinga)
08:00AM	Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Mar-17-23 07:09AM	We Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefully (Simply Wall St.) -12.36%
Mar-16-23 08:00AM	Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update (Business Wire)
Jan-26-23 08:00AM	Alzamend Neuro to Present at Sequire Biotechnology Conference (Business Wire) +9.48%
Jan-04-23 08:00AM	Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial (Business Wire)
Dec-28-22 08:00AM	Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) -11.31%
07:31AM	EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia (Benzinga)
Dec-13-22 03:52PM	10 Biotech Stocks With The Biggest Upside (Insider Monkey)
Nov-22-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc. (ACCESSWIRE) +10.62%
Nov-15-22 08:00AM	Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline (Business Wire)
Oct-31-22 08:00AM	Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Oct-11-22 10:03AM	Alzamend Neuro, Inc.'s (NASDAQ:ALZN) top owners are individual investors with 46% stake, while 21% is held by private companies (Simply Wall St.) -11.19%
Oct-05-22 12:45PM	Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial (Benzinga) +7.25%
08:00AM	Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimers Subjects (Business Wire)
Sep-29-22 12:29PM	Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Sep-22-22 08:00AM	Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement (Business Wire) -7.63%

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

CEOStephan Jackman

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AULT MILTON C III	Director	Aug 26 '26	Sale	1.56	2,000	3,116	0	Aug 31 06:05 AM
AULT MILTON C III	Director	Apr 14 '26	Buy	1.00	108,388	108,897	116,648	Apr 16 04:30 PM
AULT MILTON C III	Director	Dec 23 '25	Sale	2.07	1,851	3,825	0	Dec 30 05:54 PM
Horne William B.	Director	Dec 19 '25	Sale	2.12	3,333	7,059	0	Dec 23 04:30 PM
McGrath Lynne Fahey	Director	Oct 23 '25	Sale	2.29	30	69	25	Oct 24 04:30 PM
AULT MILTON C III	Director	Oct 08 '25	Sale	2.44	101,394	247,158	28,657	Oct 10 04:30 PM
AULT MILTON C III	Director	Oct 09 '25	Sale	2.32	20,397	47,390	8,260	Oct 10 04:30 PM
AULT MILTON C III	Director	Oct 07 '25	Sale	2.49	57,379	142,954	68,848	Oct 08 06:50 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALZN

Alzamend Neuro Inc

Upgrade your Finviz experience